AVXL UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026Newsfile Corp · 14 hr ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXLNewsfile Corp · 1 day ago
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G.PRNewsWire · 1 day ago
AVXL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026Newsfile Corp · 1 day ago
Kaplan Fox Alerts Investors of Anavex Life Sciences Corp. (AVXL) with Significant Losses to a Securities Class Action Deadline on November 30, 2026Newsfile Corp · 1 day ago
ROSEN, A NATIONAL LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXLNewsfile Corp · 2 days agoOperating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 28, 2026 | -$0.08 | -$0.03 | Beat |
| Aug 25, 2026 | -$0.08 | $0.08 | Beat |
| Feb 9, 2026 | -$0.10 | -$0.06 | Beat |
| Nov 25, 2025 | -$0.13 | -$0.11 | Beat |
| Aug 12, 2025 | -$0.13 | -$0.16 | Miss |
| May 13, 2025 | -$0.16 | -$0.13 | Beat |